Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia | Zendy

Sophie Seang | Zendy; L Schneider | Zendy; Thuy Nguyen | Zendy; Minh Patrick Lê | Zendy; Cathia Soulié | Zendy; Ruxandra Câlin | Zendy; Fabienne Caby | Zendy; M. A. Valantin | Zendy; Roland Tubiana | Zendy; Lambert Assoumou | Zendy; AnneGeneviève Marcelin | Zendy; Gilles Peytavin | Zendy; Christine Katlama | Zendy

Open Access

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

Author(s) -

Sophie Seang,

L Schneider,

Thuy Nguyen,

Minh Patrick Lê,

Cathia Soulié,

Ruxandra Câlin,

Fabienne Caby,

M. A. Valantin,

Roland Tubiana,

Lambert Assoumou,

AnneGeneviève Marcelin,

Gilles Peytavin,

Christine Katlama

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx417

Subject(s) - darunavir , ritonavir , regimen , medicine , atazanavir , lopinavir , viral load , gastroenterology , tolerability , adverse effect , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy

Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research